This is a tech story of three Indian giants, which delivered wavering quarterly results in an environment clouded with uncertainties. The largest, Tata Consultancy Services (TCS), witnessed the most ...
A phase 1 dose-escalation study of EC1456, a folic acid-tubulysin small-molecule drug conjugate, in adult patients (pts) with advanced solid tumors. Background: Gemcitabine HCl is a nucleoside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback